# Ferric Carboxymaltose (Ferinject) Infusion

### **Checklist**

	CHECK LIST	RESPONSE
1.	Baseline Measurements:	
	WeightKg *Phosphatemmol/L (if phosphate measurement indicated – see bottom of checklist).	
	Hbg/L. Ferritinug/L	
	NOTE: if pregnant, enquire on fetal movements. Check fetal heart rate pre and post infusion and document all details in the clinical notes	
2.	Is the patient antenatal, postnatal or neither.	☐ Antenatal
	If antenatal, number of week pregnant	☐ Postnatal
	(NB IV Ferric Carboxymaltose infusion contraindicated in first trimester)	☐ Neither
3.	Does the patient meet the criteria for IV iron infusion in the POAC clinical guideline?	Yes / No
4.	Have contraindications been excluded? (See POAC guideline)	Yes / No
5.	Has funded Ferinject infusion been authorised by POAC (for referrals to an infusion centre only)	Yes / No
6.	Is *phosphate >/= 0.8 mmol/L, if measurement indicated? (Note: not all patients need phosphate measuring – see bottom of checklist).  If measurement required and low, defer infusion until phosphate normal.	Yes / No/ NA
7.	Has patient been informed of potential adverse effects?	Yes / No
8.	Have the patient's questions been answered after they have read the Ferinject Patient Information Sheet?	Yes / No
9.	Has the patient signed the consent form?	Yes / No
10.	If patient <35kg has the dose of Ferric Carboxymaltose been calculated using an approved method based on patient's weight and Hb? (Refer to POAC guideline).	Yes / No/ NA
	All patients ≥ 35 kg receive 1000mg as a single dose	
*	Indications to check phosphate - the patient: has had ≥ 2 iron infusions in the last 6 months OR has had ≥ 1000mg ferric carboxymaltose and is symptomatic (weakness/bone pain/mental changes) OR is at risk of low phosphate (BMI<18/poor nutrition/chronic diarrhea)	

Ferinject Infusion – Checklist and Patient Consent for POAC document

## Ferric Carboxymaltose (Ferinject) Infusion

#### **Patient Consent**

#### **Procedure**

Intravenous infusion of Ferric carboxymaltose (Ferinject) over at least 15 minutes for Iron Deficiency Anaemia.

Consent			
I	(first name)		
	(last name)		
Date of birth:			
•	Have had explained to me the purpose and procedure of Ferric carboxymaltose (Ferinject) by intravenous infusion.		
I confirm that I have had exp	plained to me adverse effects		
<ul> <li>Have been provided with, or of the Ferinject Patient Infor</li> </ul>	r informed where to find electronic version rmation Leaflet		
Signature:			
Date:			